Mostra i principali dati dell'item
A Prospective Screening of HLA-B*57.01 Allelic Variant for Preventing the Hypersensivity Reaction to Abacavir: Experience from the Laboratory of Molecular Biology of the Infectious Diseases Division at the University Hospital of Salerno
dc.contributor.advisor | Senatore, C. | |
dc.contributor.advisor | Charlier, B. | |
dc.contributor.advisor | Truono, A. | |
dc.contributor.advisor | Punzi, R. | |
dc.contributor.advisor | D’Aniello, F. | |
dc.contributor.advisor | Boffa, N. | |
dc.contributor.advisor | Izzo, Viviana | |
dc.contributor.advisor | Conti, Valeria | |
dc.contributor.advisor | Russomanno, Giusy | |
dc.contributor.advisor | Manzo, V. | |
dc.contributor.advisor | Filippelli, Amelia | |
dc.contributor.advisor | Mazzeo M, M. | |
dc.date.accessioned | 2015-01-29T14:09:18Z | |
dc.date.available | 2015-01-29T14:09:18Z | |
dc.date.issued | 2015 | |
dc.identifier.citation | Senatore C, Charlier B, Truono A, Punzi R, D’Aniello F, Boffa N, Izzo V, Conti V, Russomanno G, Manzo V, Filippelli A, Mazzeo M. A Prospective Screening of HLA-B*57.01 Allelic Variant for Preventing the Hypersensivity Reaction to Abacavir: Experience from the Laboratory of Molecular Biology of the Infectious Diseases Division at the University Hospital of Salerno. Translational Medicine @ UniSa 2015, 11(10):55-58 | en_US |
dc.identifier.issn | 2239-9747 | en_US |
dc.identifier.uri | http://hdl.handle.net/10556/1652 | |
dc.identifier.uri | http://dx.doi.org/10.14273/unisa-456 | |
dc.description.abstract | Abacavir is a nucleoside reverse transcriptase inhibitor largely used as part of the antiretroviral therapy in Human Immunodeficiency Virus (HIV)-infected patients. Some individuals (2-9%) who start an abacavir treatment show an immunologic reaction indicated as hypersensitivity reaction syndrome (HSR) that is often responsible for therapy discontinuation and could represent a life-threatening event. Some studies demonstrated a correlation between this adverse reaction and the class I of the major histocompatibility complex (MHC) allele, HLA-B*57.01, in several populations, including Caucasians. Nowadays, International HIV treatment guidelines recommend the HLA-B*57.01 genotyping before abacavir administration to reduce the incidence of HSR. Both male and female HIV-infected patients were enrolled at the Infectious Diseases Division at the University Hospital of Salerno, and admitted to a prospective HLA-B*57.01 screening. Genetic analysis was carried out through two sequential Real-Time PCR reactions in which Sybr-Green was used. Out of 248 patients, 215 were Italians from Southern Italy and 33 were coming from several non-EU members countries. All were genotyped: 6 Italians (2.8%) and 1 of the non-EU group (3%) were identified as HLA-B*57.01 carriers. In this paper we present our experience in the field of abacavir pharmacogenetic and confirm the importance of Real Time PCR as a valid and cost-effective HLA-B*57.01 typing methodology. | en_US |
dc.format.extent | P. 55-58 | en_US |
dc.language.iso | en | en_US |
dc.source | UniSa. Sistema Bibliotecario di Ateneo | en_US |
dc.subject | Abacavir | en_US |
dc.subject | HIV | en_US |
dc.subject | HLA-B*57.01 | en_US |
dc.subject | Hypersensitivity reaction | en_US |
dc.subject | Real-Time PCR | en_US |
dc.title | A Prospective Screening of HLA-B*57.01 Allelic Variant for Preventing the Hypersensivity Reaction to Abacavir: Experience from the Laboratory of Molecular Biology of the Infectious Diseases Division at the University Hospital of Salerno | en_US |
dc.type | Article | en_US |